Potassium Citrate Tablet, Extended Release
Product Images NDC 72162-2121

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Potassium Citrate (NDC 72162-2121). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Structure)

FDA Label Image

Table 1. (Table 1.)

Table 1 shows the effect of Potassium Citrate in patients with Calcium Oxalate Nephrolithiasis. The table presents the number of stones formed per year in different groups before and after treatment. The baseline values and the values on treatment are provided for each group, along with the remission rate and any decrease in stone formation. The different groups are labeled as Group I, Group II, Group III, and Group IV, consisting of 19, 37, 15, and 18 patients, respectively. The total number of patients evaluated is 89. Remission is defined as the percentage of patients remaining free from newly formed stones during the treatment.*

FDA Label Image

Label (Lbl721622121)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.